title: Lupin seed γ-conglutin lowers blood glucose in hyperglycaemic rats and increases glucose consumption of HepG2 cells.
abstract: The aim of the present study was to evaluate the effect of a chronic oral γ-conglutin treatment in male Sprague-Dawley rats in which hyperglycaemia had been induced by supplying 10 % d-glucose in drinking-water. A γ-conglutin dosage of 28 mg/kg body weight was daily administered to animals for 21 d. Plasma glucose, insulin and glucose overloading were monitored. Chronic administration of glucose resulted in a statistically significant (P < 0·05) increase in fasting blood glucose (2·5-fold) and insulin (2·7-fold) v. the values recorded in control rats. Simultaneous treatment with γ-conglutin attenuated the rise in plasma glucose (1·9-fold) and insulin (1·8-fold) levels in the glucose-fed rats (P < 0·05). Fasting insulin and homeostasis model of insulin resistance were decreased by 34 and 48 % (P < 0·05), respectively, in the γ-conglutin-treated rats v. the values found in pair-fed animals. To confirm these results with a different approach, HepG2 cells, grown for 24 and 48 h in Dulbecco's minimum essential medium containing different glucose concentrations (5·5, 11·1 and 16·5 mmol/l), were exposed to 10 μmol/l γ-conglutin with or without 10 mmol/l metformin or 100 nmol/l insulin. γ-Conglutin increased glucose consumption (from 1·5- to 2·5-fold) in HepG2 cells, under all experimental conditions; this effect was more evident after 48 h incubation. Moreover, in this in vitro model, the addition of γ-conglutin potentiated the activity of insulin and metformin in cell glucose consumption. These findings extend the previous ones and suggest the potential use of lupin γ-conglutin in the control of glycaemia.
authors: Department of Pharmacological Sciences, Università degli Studi di Milano, 20133 Milano, Italy. mariarosa.lovati@unimi.it
authors: Maria Rosa
authors: MR
authors: Lovati
authors: Cristina
authors: C
authors: Manzoni
authors: Silvia
authors: S
authors: Castiglioni
authors: Anna
authors: A
authors: Parolari
authors: Chiara
authors: C
authors: Magni
authors: Marcello
authors: M
authors: Duranti
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D004044:Dietary Proteins / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D019587:Dietary Supplements / Q000032:analysis; D005947:Glucose / Q000009:adverse effects / Q000378:metabolism*; D056945:Hep G2 Cells; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000178:diet therapy* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology; D007328:Insulin / Q000097:blood / Q000378:metabolism; D007333:Insulin Resistance; D031297:Lupinus / Q000737:chemistry*; D008297:Male; D008687:Metformin / Q000494:pharmacology; D010940:Plant Proteins / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012639:Seeds / Q000737:chemistry*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D004044:Dietary Proteins; D007004:Hypoglycemic Agents; D007328:Insulin; D010940:Plant Proteins; C079483:conglutin-gamma protein, Lupinus angustifolius; D008687:Metformin; D005947:Glucose